Association between a selective 5-ht₄ receptor agonist and incidence of major depressive disorder: emulated target trial

HIGHLIGHTS

• What: Using this approach, the authors assessed whether exposure to the 5-HT4R agonist prucalopride (an anti-constipation agent acting on 5-HT4R in the gut, but also with good brain penetration14) is associated with a lower risk of depression within 1 year since first prescription, compared with two alternative anti-constipation agents that have no known effect on 5-HT4Rs or the central nervous system. The three drugs compared in this study have the same clinical indication, and the cohorts were well matched on a wide range of covariates at baseline. The study has several strengths . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.